The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study
DOI:
https://doi.org/10.2340/actadv.v105.44310Keywords:
Prurigo nodularis, Nemolizumab, systemic therapy, cutaneous adverse events, Th2Downloads
References
Pereira MP, Steinke, S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059–1065. DOI: https://doi.org/10.1111/jdv.14570
Kwatra SG, Ständer S, Yosipovitch G, Kim BS, Levit NA, O’Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of Type 2 inflammation. J Invest Dermatol 2025; 145: 249–256. DOI: https://doi.org/10.1016/j.jid.2024.06.1276
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29: 1180–1190. DOI: https://doi.org/10.1038/s41591-023-02320-9
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389: 1579–1589. DOI: https://doi.org/10.1056/NEJMoa2301333
US Food and Drug Administration. Novel drug approvals for 2024. Available from: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
Mima Y, Yamamoto M, Iozumi K. Cutaneous adverse events following nemolizumab administration: a review. J Clin Med 2025; 14: 3026. DOI: https://doi.org/10.3390/jcm14093026
Mima Y, Yamamoto M, Iozumi K. Transient elevation of eosinophil and thymus and activation-regulated chemokine levels associated with cutaneous adverse events due to nemolizumab: a case report. Dermatitis 2025 Sep 12. [Online ahead of print]. DOI: https://doi.org/10.1177/17103568251380242
Mima Y, Ohtsuka T. A Case of erythema multiforme following the administration of nemolizumab. Cureus 2025; 17: e79070. DOI: https://doi.org/10.7759/cureus.79070
Mima Y, Yamamoto M, Iozumi K. Four cases of prurigo nodularis requiring nemolizumab due to persistent pruritus or lesions after dupilumab treatment. Acta Derm Venereol 2025; 105: adv43419. DOI: https://doi.org/10.2340/actadv.v105.43419
Mima Y, Yamamoto M, Iozumi K. Effectiveness of nemolizumab in improving dialysis-associated pruritus refractory to difelikefalin: a case report. Cureus 2025; 17: e83367. DOI: https://doi.org/10.7759/cureus.83367
Sasaki W, Saito R, Suzuki K, Watanabe D, Minami-Hori M, Kamada H, et al. Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan. J Dermatol 2025 Jul 23. [Online ahead of print]. DOI: https://doi.org/10.1111/1346-8138.17877
Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752–760. DOI: https://doi.org/10.1038/ni1084
Bilsborough J, Mudri S, Chadwick E, Harder B, Dillon SR. IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M. J Immunol 2010; 185: 6023–6030. DOI: https://doi.org/10.4049/jimmunol.0902769
Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141–150. DOI: https://doi.org/10.1056/NEJMoa1917006
Sekiya T, Tsunemi Y, Miyamasu M, Ohta K, Morita A, Saeki H, et al. Variations in the human Th2-specific chemokine TARC gene. Immunogenetics 2003; 54: 742–745. DOI: https://doi.org/10.1007/s00251-002-0520-2
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Yoshihito Mima, Masako Yamamoto, Ken Iozumi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
